Get directly involved in the fight against cancer! Join us and become an investor in Cambium Oncology.
In the dynamic field of cancer immunotherapy, the search for more effective treatments is ongoing. Despite remarkable advancements, current therapies offer most patients have limited benefit. This is the unmet need addressed by Cambium Oncology.
Our pioneering work is breaking new ground in developing next-generation checkpoint inhibitors and therapeutic antibodies. Our innovative approach has demonstrated promising potential and is poised to revolutionize cancer treatment and enhance patient outcomes.
Cambium Oncology isn’t just a biotech company; we have developed a new vision for cancer immunotherapy. By investing with us, you’re not only contributing to the advancement of groundbreaking medical science, but you’re also joining a passionate team committed to making a tangible difference in the lives of cancer patients worldwide.
Embark on this journey with us and be a part of a brighter, healthier future — your support matters!
- Early exit possible; don’t have to complete Phase I/II to reach a liquidity event.
- More than one shot-on-goal; we have two backup molecules if our lead therapeutic candidate needs to be replaced.
- More than one shot-on-goal: we have encouraging preclinical data for a second indication (pancreatic cancer).
- Our lead therapeutic candidate is safe and effective in our pre-IND studies: no toxicity-limiting dosages seen.
- No hematological toxicity; no immunological toxicity; not cytotoxic
- We have identified a promising, novel target
Become an investor in Cambium Oncology and add your support to the fight against cancer.
Join us and our Founder and Chief Science Officer Edmund K. Waller in the fight against cancer!
Edmund K. Waller, MD, PhD, FACP, is board certified in hematology, medical oncology and internal medicine. A practicing physician with Emory Healthcare since 1995, Dr. Waller specializes in bone marrow transplants for acute leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, lymphoma, aplastic anemia, sickle cell disease and in the management of graft-versus-host disease (GVHD). He is also an expert in CAR T-cell therapy.
Dr. Waller holds memberships with American College of Physicians, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology and International Society for Experimental Hematology.
Dr. Waller earned his undergraduate degree from Harvard University, his medical degree from Cornell University Medical College, and his PhD in chemical biology from Rockefeller University in New York, New York. Dr. Waller completed a residency in the Department of Medicine at Stanford University in Stanford, California. He then went on to complete a clinical fellowship in oncology, as well as a research fellowship in pathology at Stanford University.
Dr. Waller’s research focus is in enhancing immune reconstitution after stem cell transplant and anti-tumor immunology. He has research support from the National Institutes of Health, The Leukemia & Lymphoma Society and National Marrow Donor Program.
In addition to being our Chief Science Officer, Dr. Waller holds the following appointments:
Rein Saral, MD Professorship in Cancer Medicine Winship Cancer Institute of Emory University
Professor, Departments of Medicine, Pathology, and Hematology and Medical Oncology Emory University School of Medicine
Medical Director, Center for Stem Cell Processing and Apheresis Emory University Hospital
Director, Center for Regenerative Engineering and Medicine Emory University, Georgia Tech and The University of Georgia
Meet the rest of our team
Please send me an email with your questions or let’s schedule a call.
Gary G Altman, PhD, CEO